Clinical trial
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic…
NCT00428597 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00428597 |
|---|---|
| Title | A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors |
| Official title | A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Islet Cell, Pancreas |
| Intervention type | Drug |
| Interventions | sunitinib malate, Placebo |
| Enrollment | 171 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jan 30, 2007 |
| Last update posted | Oct 11, 2010 |
| Countries | Australia, Belgium, Canada, France, Germany, Italy, South Korea, Spain, Taiwan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: